Treatment for osteoarthritis by intra-articular administration of a cis-imidazoline
Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
1. A method of treating osteoarthritis, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to Formula (I), or a pharmaceutically acceptable salt thereof:
wherein R is selected from saturated and unsaturated 5- and 6-membered rings containing at least one hetero atom, wherein the hetero atom is selected from S, N and O and is optionally substituted with a group selected from lower alkyl, cycloalkyl, —C═O—R 1 , hydroxy, lower alkyl substituted with hydroxy, lower alkyl substituted with lower alkoxy, lower alkyl substituted with —NH 2 , lower alkyl substituted with —C═O—R 1 , N-lower alkyl, —SO 2 CH 3 , ═O and —CH 2 C═OCH 3 ;
R 1 is selected from hydrogen, lower alkyl, —NH 2 , —N-lower alkyl, lower alkyl substituted with hydroxy, lower alkyl substituted with —NH 2 , and a 5- or 6-membered saturated ring containing at least one hetero atom selected from S, N and O;
X 1 and X 2 are each independently selected from hydrogen, lower alkoxy, —CH 2 OCH 3 , —CH 2 OCH 2 CH 3 , —OCH 2 CF 3 , and —OCH 2 CH 2 F; and
Y 1 and Y 2 are each independently selected from —Cl, —Br, —NO 2 , —C≡N, and —C≡CH.
2. The method of claim 1 , wherein R is piperazin-2-one.
3. The method of claim 1 , wherein Y 1 and Y 2 are both chloride.
4. The method of claim 1 , wherein X 1 and X 2 are —O—CH—(CH 3 ) 2 and —O—CH 3 respectively.
5. The method of claim 1 , wherein the compound is administered intra-articularly to an osteoarthritic joint in the subject.
6. The method of claim 1 , wherein the compound is formulated in a pharmaceutical composition that contains a hyaluronan.
7. The method of claim 1 , wherein the compound is formulated in a sustained release formulation that includes a gel, a polymeric matrix, or a microparticle.
8. The method of claim 1 , wherein the compound is administered as a single dose, followed by a non-treatment interval of at least two weeks.
9. The method of claim 5 , whereby erosion of a proteoglycan layer is inhibited in the osteoarthritic joint.
10. The method of claim 5 , whereby production of collagen Type II is promoted in the osteoarthritic joint.
11. The method of claim 5 , whereby symptoms of osteoarthritis being experienced by the subject in the joint are relieved.
12. The method of claim 5 , whereby pain being experienced by the subject in the joint is relieved.
13. The method of claim 1 , wherein the compound is 4-[[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone.
14. The method of any of claims 2 to 12 , wherein the compound is 4-[[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone.